Kidney Cancer Clinical Trial
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
- Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy
- Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders
Renal Cell Carcinoma with clear cell component
Receiving IO-containing regimen
Measurable disease per RECIST 1.1
Active cancer (exclusion criteria only for healthy patient cohort)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.